Sarepta Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how much money the company made and spent that quarter, helping investors track business performance.
Provides complete financial statements and detailed information about company assets, debts, and operations.
Leadership changes can affect company direction and strategy, important for investors to track management.
Allows company to offer stock rewards to employees, affecting future share ownership and company costs.
Shows company earnings and spending for the first quarter, helping track performance trends.
Provides complete financial statements and detailed information about company assets, debts, and operations.
Year-end financial statements show total profits, losses, and financial position for the entire year.
Stocky reads Sarepta Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Sarepta Therapeutics, Inc.'s most recent tracked filing was a 8-K on 5 Aug 2026: Sarepta reports Q2 2026 financial results on August fifth.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.